Protara Therapeutics Stock Performance

TARA Stock  USD 7.00  0.08  1.13%   
On a scale of 0 to 100, Protara Therapeutics holds a performance score of 8. The company holds a Beta of 1.51, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Protara Therapeutics will likely underperform. Please check Protara Therapeutics' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Protara Therapeutics' historical price patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Protara Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Protara Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
1.14
Five Day Return
16.07
Year To Date Return
31.6
Ten Year Return
(98.06)
All Time Return
(98.24)
Last Split Factor
1:40
Dividend Date
2020-01-10
Last Split Date
2020-01-10
1
Acquisition by Fabbio Patrick of 131000 shares of Protara Therapeutics at 1.91 subject to Rule 16b-3
11/07/2025
2
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphat...
11/18/2025
3
Protara Therapeutics starts 75M stock and pre-funded warrant sale - Stock Titan
12/04/2025
4
Protara Announces Closing of 75 Million Public Offering
12/08/2025
5
Why Protara Therapeutics Inc. stock could outperform in 2025 - Portfolio Performance Report High Accuracy Investment Signals -
12/19/2025
6
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
01/05/2026
7
XRP Retrace Is Only Temporary, What Happens Once the Uptrend Resumes
01/08/2026
8
TARA Media, SWYM.ai Bring AI-Powered Supply Shaping to Media Buying Platform
01/15/2026
9
Disposition of 2132 shares by Hannah Fry of Protara Therapeutics at 5.6 subject to Rule 16b-3
01/20/2026
10
Acquisition by Hannah Fry of 9500 shares of Protara Therapeutics subject to Rule 16b-3
01/21/2026
11
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Canc...
01/22/2026
12
Disposition of 3724 shares by Zummo Jacqueline of Protara Therapeutics at 6.67 subject to Rule 16b-3
01/26/2026
13
BYOMA ANNOUNCES NEW GLOBAL PRESIDENT AND CHIEF BRAND OFFICER
01/27/2026
Begin Period Cash Flow40.3 M
Total Cashflows From Investing Activities19.2 M

Protara Therapeutics Relative Risk vs. Return Landscape

If you would invest  512.00  in Protara Therapeutics on November 3, 2025 and sell it today you would earn a total of  188.00  from holding Protara Therapeutics or generate 36.72% return on investment over 90 days. Protara Therapeutics is currently generating 0.6967% in daily expected returns and assumes 6.2942% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Protara, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Protara Therapeutics is expected to generate 8.49 times more return on investment than the market. However, the company is 8.49 times more volatile than its market benchmark. It trades about 0.11 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Protara Therapeutics Target Price Odds to finish over Current Price

The tendency of Protara Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 7.00 90 days 7.00 
about 5.93
Based on a normal probability distribution, the odds of Protara Therapeutics to move above the current price in 90 days from now is about 5.93 (This Protara Therapeutics probability density function shows the probability of Protara Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.51 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Protara Therapeutics will likely underperform. Additionally Protara Therapeutics has an alpha of 0.5982, implying that it can generate a 0.6 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Protara Therapeutics Price Density   
       Price  

Predictive Modules for Protara Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protara Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.686.9713.26
Details
Intrinsic
Valuation
LowRealHigh
5.2011.4917.78
Details
Naive
Forecast
LowNextHigh
1.067.3513.65
Details
7 Analysts
Consensus
LowTargetHigh
23.2125.5028.31
Details

Protara Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Protara Therapeutics is not an exception. The market had few large corrections towards the Protara Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Protara Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Protara Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.60
β
Beta against Dow Jones1.51
σ
Overall volatility
0.82
Ir
Information ratio 0.10

Protara Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protara Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protara Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Protara Therapeutics is way too risky over 90 days horizon
Protara Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (44.6 M) with profit before overhead, payroll, taxes, and interest of 0.
Protara Therapeutics currently holds about 98.46 M in cash with (35.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Protara Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from simplywall.st: Were Not Very Worried About Microbot Medicals Cash Burn Rate

Protara Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protara Stock often depends not only on the future outlook of the current and potential Protara Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protara Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding20.6 M
Cash And Short Term Investments170.3 M

Protara Therapeutics Fundamentals Growth

Protara Stock prices reflect investors' perceptions of the future prospects and financial health of Protara Therapeutics, and Protara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protara Stock performance.

About Protara Therapeutics Performance

By analyzing Protara Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Protara Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Protara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.23)(0.24)
Return On Capital Employed(0.33)(0.35)
Return On Assets(0.22)(0.23)
Return On Equity(0.31)(0.32)

Things to note about Protara Therapeutics performance evaluation

Checking the ongoing alerts about Protara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Protara Therapeutics is way too risky over 90 days horizon
Protara Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (44.6 M) with profit before overhead, payroll, taxes, and interest of 0.
Protara Therapeutics currently holds about 98.46 M in cash with (35.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Protara Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from simplywall.st: Were Not Very Worried About Microbot Medicals Cash Burn Rate
Evaluating Protara Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Protara Therapeutics' stock performance include:
  • Analyzing Protara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protara Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Protara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Protara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protara Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Protara Therapeutics' stock. These opinions can provide insight into Protara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Protara Therapeutics' stock performance is not an exact science, and many factors can impact Protara Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Protara Stock analysis

When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years